Clinical Results

With 8 years’ median follow-up (range 74-117 months), in a challenging group of 31 highly recurrent NMIBC patients where multiple bladder instillations had failed, BWT resulted in a median 7X extension of the recurrence-free interval (RFI) compared to each patient baseline thus reducing both the pain and cost of 6 surgeries.

Characteristics at baseline: 10/31 high-risk, 21/31 intermediate-risk; median RFI was 5 months (range 3-16 months); median number of recurrences was 5 (range 2-16); all 31 patients failed intravesical BCG, 10 failed also MMC instillations and 6 failed also microwave thermo-chemotherapy instillations.

All 31 patients treated with the same early protocol: there were 6 weekly induction procedures followed by 6 monthly maintenance procedures; drug solution concentration was 40mg MMC in 50ml water, bladder temperature was 44.0-44.5°C and treatment time was 50 minutes. 

It’s important to note that today, there are two BWT protocols: A standard one and an enhanced one. 

 Treatment temperature (44°-44.5°C) and treatment duration (50 min) in current protocols remained the same as in the early protocol.

An #X extension of RFI was calculated for each patient by dividing his post BWT RFI by his baseline RFI. Sixteen patients had no recurrence (of them 7 died recurrence-free, unrelated to bladder cancer) and 15 patients recurred. 

30/31 patients benefited from BWT by achieving 2X-26X extended RFI (median 7X). 

The RFI extension for each patient is shown in the next page.

Related Articles
  • BMRI2013-262313 Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
  • BWT for NMIBC - Prof. Rassweiler Germany 2017 Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer
  • BWT Brussels abstract for Global Congress for Bladder Cancer - Prof. Tsivian Israel 2018 Bladder Wall Thermo-chemotherapy (BWT) Instillations for Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Chemohyperthermia in non muscle invasive bladder cancer Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations
  • Efficacy and safety of UniThermia Treatment - World J Urol - Prof. Gontero Italy 2015 Efficacy and safety of a new device for intravesical thermochemotherapy in non‑grade 3 BCG recurrent NMIBC: a phase I–II study
  • Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder cancer - Division of Urology Duke University
  • Thermo-chemo based on BWT - Pharma study 2014 Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients
  • Hyperthermic Intravesical Chemotherapy UniThermia - Prof. Beat Roth Switzerland 2024 Hyperthermic Intravesical Chemotherapy (UniThermia) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy
  • Intravesical Mitomycin-C with Bladder Wall Hyperthermia in Intermediate and High-risk Non-muscle Invasive - Prof. Demirtas Turkey 2020 Intravesical Mitomycin-C with Bladder Wall Hyperthermia in Intermediate and High-risk Non-muscle Invasive Bladder Cancers: Prospective Clinical Trial with a Singletreatment Arm